Rapid Micro Biosystems Revenue and Competitors
Estimated Revenue & Valuation
- Rapid Micro Biosystems's estimated annual revenue is currently $23.3M per year.
- Rapid Micro Biosystems received $60.0M in venture funding in May 2018.
- Rapid Micro Biosystems's estimated revenue per employee is $105,727
- Rapid Micro Biosystems's total funding is $358.4M.
- Rapid Micro Biosystems's current valuation is $301M. (January 2022)
Employee Data
- Rapid Micro Biosystems has 220 Employees.
- Rapid Micro Biosystems grew their employee count by 5% last year.
Rapid Micro Biosystems's People
Name | Title | Email/Phone |
---|---|---|
1 | CFO | Reveal Email/Phone |
2 | SVP and General Counsel | Reveal Email/Phone |
3 | VP, Quality and Regulatory Affairs | Reveal Email/Phone |
4 | VP Operations | Reveal Email/Phone |
5 | Director Continuous Improvement | Reveal Email/Phone |
6 | Director Global Sales Operations | Reveal Email/Phone |
7 | Sr. Director Financial Planning & Analysis | Reveal Email/Phone |
8 | Chief Human Resources Officer | Reveal Email/Phone |
9 | Director, Total Rewards, HRIS & Analytics | Reveal Email/Phone |
10 | Senior Director, Supply Chain Management | Reveal Email/Phone |
Rapid Micro Biosystems Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Rapid Micro Biosystems?
Rapid Micro Biosystems creates innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company's Growth Directthe first and only growth-based system to automate compendial testingdetects contamination more quickly, delivering compelling economic benefits to manufacturers while improving their quality control (QC) process. Growth Direct addresses all key microbial QC applications and fits with current regulatory practices, a critical accelerator for adoption. Automated, accelerated analysis eliminates error-prone manual steps and saves labor. Rapid detection of contamination enables manufacturers to reduce inventory carrying costs, shorten manufacturing cycles, and reduce product losses, delivering significant cost savings and increased operational efficiency. Rapid Micro Biosystems' proprietary technology is based on the detection of natural autofluorescence. The inventors of the core principle, efficient blue light-emitting diodes, which has enabled bright and energy-saving white light sources, won the Nobel Prize in Physics. Rapid Micro Biosystems is headquartered in Lowell, Massachusetts, with operations in Lowell and Freising, Germany.
keywords:Biotechnology,Hardware,Hardware Peripherals,Healthcare,Human Resources Hr,Medical Diagnostics,Pharmaceuticals$358.4M
Total Funding
220
Number of Employees
$23.3M
Revenue (est)
5%
Employee Growth %
$301M
Valuation
N/A
Accelerator
Rapid Micro Biosystems News
In 2020, it contributed to Rapid Micro Biosystems' $120 million financing round, and in 2019, the Tokoyo-based company purchased the...
Rapid Micro Biosystems, Inc provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology,...
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the...
- Longitude Prime Fund makes first investment in IPO of Rapid Micro Biosystems, the industry leading automated quality-control platform for pharmaceutical manufacturing - MENLO PARK, Calif., GREENWICH, Conn., and BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Longitude Capital, a leading healthcare ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 243 | 6% | N/A |
#2 | $15M | 250 | N/A | N/A |
#3 | $99.1M | 279 | 5% | N/A |
#4 | $128M | 353 | 4% | N/A |
#5 | $15M | 373 | 21% | N/A |
Rapid Micro Biosystems Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2005-08-15 | $4.1M | Second | Ntl Institute of Allergy and I | Article |
2009-07-09 | $18.6M | A | Article | |
2013-06-27 | $32.6M | B | Longitude Capital, TPG Biotech | Article |
2014-04-14 | $6.0M | Undisclosed | Article | |
2014-12-16 | $19.0M | Undisclosed | GE Capital | Article |
2015-04-30 | $25.0M | Undisclosed | Hepalink USA Inc. | Article |
2018-05-03 | $60.0M | Undisclosed | Bain Capital | Article |